Joel takes a look at the RIVUR trial discussion from 2014, and a recent research study that makes us rethink the RIVUR results.
Background
This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
Background
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
Background
This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.
Background
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
